The Oxford Vaccine Group is recruiting infants aged 4 – 7 months to a type 1 diabetes prevention trial. POInT (Primary Oral Insulin Trial) is recruiting infants who were screened for diabetes at birth through the INGR1D Study and have been found to be at high risk for developing diabetes.

Be on the TEAM: Teenagers against Meningitis

The Oxford Vaccine Group are inviting students in school year 12 to take part in a research project to understand whether immunising teenagers with vaccines against ‘Meningitis B’ could protect them and the rest of the community against these potentially deadly bacteria. This is a national study involving 24 000 year 12 students across the United Kingdom.  Teenagers at participating schools are being asked to take part by local research teams involved.

Meningococcal B Booster Vaccine in Young People

Would you like your child to be vaccinated against Meningococcal B disease?

The Oxford Vaccine Group are inviting healthy children with a birthday between 25/06/2006 and 17/12/2006 to take part in a meningitis research study. 

Meningococcal bacteria can cause meningitis (swelling of the covering of the brain) or septicaemia (blood poisoning), or a combination of these symptoms.

The study involves receiving two doses of the licensed 4CMenB (Bexsero®) vaccine to protect against meningococcal group B disease, and four blood tests taken over a year.

Investigating a new Vaccine Against Meningitis B in Oxford VAMBOX

You are invited to take part in a study to investigate a new Vaccine Against Meningitis B in Oxford (VAMBOX). The study is being run by the Oxford Vaccine Group at the University of Oxford.

If you are 18 to 50 yrs old and are in good health, then you may be eligible to take part in the study. We will provide reimbursement for your time, inconvenience and travel. Participants will receive up to £630.00 if they remain in the study for the entire period. The total study participation time is 12 months.


Developing a vaccine to prevent RSV, a cause of serious respiratory infections in infants (children)

Respiratory syncytial virus (RSV) is a highly infectious respiratory virus that infects the lungs and breathing passages. In children RSV infection typically occurs at least once a year and in adults every 3-5 years during the winter season. RSV is considered to be one of the most important causes of serious acute respiratory illness in infants and children under 5 years of age. Children usually experience mild to moderate cold-like symptoms and recover in a few days to a week. However, some infants require hospital admission and sometimes need a ventilator to help with breathing.

Understanding RSV: Severe disease and the long term consequences

Oxford Vaccine Group are currently inviting children under 12 months of age to take part in a study which will help us learn more about the virus that most commonly causes coughs, colds and chest infections in young children and can sometimes cause children to be so unwell they have to be admitted to hospital.

More than half of children will be infected with the virus, called Respiratory Syncytial Virus (RSV) in their first year of life, mostly during the winter.

Burden of RSV Disease

Some facts about RSV disease (respiratory syncytial virus):

RSV is a virus;

  • it causes coughs, colds and chest infections
  • is responsible for around 1 in 6 hospital admissions for infants  in the UK
  • The second largest worldwide cause of deaths in children between one month and 1 year of age, most are in Asia and Africa

What do we want to do?

We would like to identify 2000 babies from birth and follow them up to see if any become unwell with RSV disease

ImmunoglobuliN in the Treatment of Encephalitis

The IgNiTE Study

A study testing a new treatment for children with encephalitis.

The Department of Paediatrics at the University of Oxford, in collaboration with NHS Trusts across the United Kingdom, is currently running a study for hospitalised children with encephalitis. The study will assess whether a treatment called intravenous immunoglobulin (IVIg, sometimes referred to as antibody treatment) has any benefit for these children when given early during the hospital admission.

Subscribe to Trials - Oxford Vaccine Group RSS